Suppression of testicular function using two dose rates of a reversible water soluble gonadotrophin releasing hormone (GnRH) vaccine in colts.
OBJECTIVE
To investigate the effect of two dose rates (200 and 400 ng) of a gonadotrophin releasing hormone (GnRH) vaccine on testicular function.


METHODS
A vaccination dose rate experiment.


METHODS
Two injections were administered 4 weeks apart to six colts in each treatment group. To maintain immunosuppression until the end of the breeding season, a third injection was given if antibody titres fell below 1000.


RESULTS
Effective antibody titres were present for 12 to 27 weeks. Testosterone concentrations decreased from 2.22 to 0.31 nmol/L 6 weeks after primary vaccination. Androstenedione concentrations decreased from 1.78 to 0.28 nmol/L 5 weeks after vaccination. Testosterone and androstenedione concentrations above 0.69 and 0.87 nmol/L were attained 31 to 43 weeks after vaccination. Mean scrotal widths and lengths decreased over 29 weeks from 9.2 cm and 9.7 cm to 6.7 cm and 7.6 cm. At surgical castration these dimensions were 10.1 cm and 11.0 cm. Mean semen characteristics before vaccination and after recovery were: gel-free volume 16.5 and 13.5 mL, sperm concentration 295.5 x 10(6) and 315.6 x 10(6)/mL, total sperm per ejaculate 4041 x 10(6) and 4657 x 10(6) and live normal spermatozoa 32% and 60%. Histologically, the testes showed active spermatogenesis. The mean testicular parenchyma weights for the 200 and 400 mg groups were 129.0 g and 109.8 g. Daily sperm production per testis and per gram of testis for the 200 and 400 mg groups were 3.7 x 10(8) and 2.8 x 10(6), and 2.3 x 10(8) and 2.0 x 10(6).


CONCLUSIONS
Both dose rates suppressed testicular function. Data showed that the vaccine effects were reversible. Individual immune response was less varied in the 200 mg group. Further work is necessary to achieve a less variable response in the immunosuppression of testicular function.
Department of Farm Animal Medicine and Production, University of Queensland, New South Wales.
K F
KF
Dowsett
L M
LM
Knott
U
U
Tshewang
A E
AE
Jackson
D A
DA
Bodero
T E
TE
Trigg
D000735:Androstenedione / Q000097:blood; D000818:Animals; D000906:Antibodies / Q000032:analysis / Q000276:immunology; D001835:Body Weight / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D007987:Gonadotropin-Releasing Hormone / Q000276:immunology / Q000494:pharmacology*; D006736:Horses / Q000097:blood / Q000502:physiology*; D008297:Male; D011863:Radioimmunoassay / Q000662:veterinary; D012661:Semen / Q000502:physiology; D013091:Spermatogenesis / Q000502:physiology; D013737:Testis / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology*; D013739:Testosterone / Q000097:blood; D014612:Vaccines / Q000276:immunology / Q000494:pharmacology*
D000906:Antibodies; D014612:Vaccines; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D000735:Androstenedione